How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paclitaxel-bevacizumab-liposomal-doxorubicin-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine (Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy with anti-angiogenic monoclonal antibody. Area: Oncology.

phase 3 Combination chemotherapy with anti-angiogenic monoclonal antibody Multiple: microtubules (paclitaxel), VEGF (bevacizumab), DNA (doxorubicin), thymidylate synthase (capecitabine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine (Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine) — Borstkanker Onderzoek Groep. This combination regimen uses multiple chemotherapy agents and an anti-angiogenic antibody to kill cancer cells through distinct mechanisms: microtubule stabilization, vascular disruption, DNA intercalation, and antimetabolite activity.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine TARGET	Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine	Borstkanker Onderzoek Groep	phase 3	Combination chemotherapy with anti-angiogenic monoclonal antibody	Multiple: microtubules (paclitaxel), VEGF (bevacizumab), DNA (doxorubicin), thymidylate synthase (capecitabine)
gemcitabine, cisplatin and bevacizumab	gemcitabine, cisplatin and bevacizumab	Fundacion Clinic per a la Recerca Biomédica	marketed	Combination chemotherapy with anti-angiogenic monoclonal antibody	DNA (gemcitabine, cisplatin); VEGF (bevacizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy with anti-angiogenic monoclonal antibody class)

Borstkanker Onderzoek Groep · 1 drug in this class
Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-bevacizumab-liposomal-doxorubicin-capecitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab